Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Prevalence of CYP2C19 Gene Polymorphism in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
Author(s): Maya Rosana Amalia , Susi Herminingsih Added: 2 years ago

Prevention & Chronic Conditions
Author(s): Suzanne J Baron , Robert P Giugliano Added: 3 years ago
Coronary artery disease remains the leading cause of death in the US and worldwide. Although the incidence of death due to coronary artery disease has declined over the last several years, the prevalence of coronary artery disease remains high, with the American Heart Association (AHA) estimating that over 81 million Americans suffer from cardiovascular disease and 2,200 people dying every day of… View more

Anticoagulation
Anticoagulant Therapy in Coronary Artery Disease
Author(s): Maki Komiyama , Gheorghe-Andrei Dan , Koji Hasegawa Added: 1 year ago

Anticoagulation

Vascular Disease and Surgery
Author(s): Kerry Layne , Albert Ferro Added: 3 years ago
Acute coronary syndrome (ACS) is a term used to encompass unstable angina (UA) and myocardial infarction (MI) with or without electrocardiographic (ECG) evidence of ST-segment elevation. Antiplatelet therapy has formed the backbone of ACS management for decades and the drug class continues to evolve as novel agents with increasingly efficacious antiplatelet actions are identified. The main risk… View more

Anticoagulation
ESC 22: Dosing of Asundexian in Pts With Non-Cardioembolic Ischemic Stroke
Author(s): Ashkan Shoamanesh Added: 1 year ago
ESC Congress 22 — Prof Ashkan Shoamanesh (McMaster University, CA) reveals the findings of the PACIFIC-STROKE trial (NCT04304508). This multicenter study aims to find the best dose of oral FXIa inhibitor, asundexian (Bayer). 1808 patients with non-cardioembolic ischemic stroke were included in this trial, and were randomized to receive different doses of asundexian. Questions: What doses were… View more

Anticoagulation

Prevention & Chronic Conditions
ACC 22: FFR vs. IVUS-guided PCI in Intermediate Coronary Artery Stenosis: The FLAVOUR Trial
Author(s): Bon-Kwon Koo Added: 2 years ago
In this short interview from our coverage of ACC.22 late-breaking trials, Dr Bon Kwon Koo (Seoul National University Hospital, KR) discusses the FLAVOUR trial (NCT02673424). FLAVOUR was a multicentre, non-inferiority, randomised clinical trial which sought to compare the safety and efficacy of FFR-guided stenting and IVUS-guided stenting. Presented first at ACC.22, the trial demonstrated that… View more

Intervention
Author(s): Diego Penela , Maríbel Diaz-Ricart , Magda Heras Added: 3 years ago
The usual underlying mechanism of acute coronary syndromes (ACSs) is a thrombotic event caused by the rupture or erosion of an atherosclerotic plaque. In this scenario, platelets and thrombin are key players. Thus, understanding the physiopathology of platelet activation is of paramount importance in the treatment of acute coronary ischaemia. There is ample evidence showing that adequate… View more

Anticoagulation

MI/ACS
P2Y12 Inhibitors for Special Populations in the Asia-Pacific Region
Author(s): Jack Wei Chieh Tan , Derek P Chew , Kin Lam Tsui , et al Added: 2 years ago

Vascular Disease and Surgery

MI/ACS
Author(s): Olaf Schouten , Don Poldermans Added: 3 years ago
Percutaneous coronary angioplasty with stenting is commonly used for treatment of symptomatic coronary artery disease (CAD). The introduction of stents has reduced the incidence of restenosis, one of the major drawbacks of coronary angioplasty, and proved to be an alternative treatment for bypass surgery. Recently, drug-eluting stents were introduced as a means to lower restenosis rates even… View more

Intervention
Summary of Current Guidelines Recommendations for Antithrombotic Therapy
Author(s): Christopher N Floyd Added: 3 years ago
Antiplatelet therapy represents a key pharmacological pillar for the prevention of atherothrombotic events. Aspirin, the primogenial antiplatelet agent, has been shown to reduce the incidence of recurrent major adverse cardiovascular events (MACE) by approximately one-fifth.1 Dual antiplatelet therapy (DAPT), usually aspirin in combination with a P2Y12 inhibitor, provides greater platelet… View more

Anticoagulation

Standards & Guidelines